This is compatible with the well known effect of IFNβ on inflammation and MRI activity in MS, and the marked drop in MRI activity and alteration in the concentrations of inflammation markers between month 6 and 7 recorded in this study. This evidence concerns the gene IFNB1 and myeloid sarcoma.